Biomolecules tagged with fluorine-18, a positron emitter with a half-life of 110 min, are gaining importance in diagnostic nuclear medicine for measuring regional functions in-vivo by means of positron emission tomography. Procedures for introducing 18 F into organic compounds, however, are limited due to the short half-life. In addition, the toxicity of many fluorine compounds requires practically carrier-free products. Hence, fast syntheses have to be carried out using fluorinating agents in the micro- or nanogram scale. On the other hand, the tracer provides unique possibilities for studying metabolic functions of toxic or centrally active fluorine compounds in-vivo. We have synthesized several aliphatic and aromatic fluorine-18 labelled compounds by nucleophilic 18 F-for-halogen exchange: For the study of regional metabolism in heart and liver of mice 16- 18 F-hexadecanoic acid, 17- 18 F-heptadecanoic acid, 2- 18 F-, and (9,10)- 18 F-stearic acid were prepared in a mixture of molten acetamide and the corresponding bromofatty acid ester followed by hydrolysis and purification by high pressure liquid chromatography. Variation of temperature, reaction time, and KF- carrier finally led to an optimum radiochemical yield of about 30% [1]. The biochemical effects of the fluorine label, as expected on the basis of β-oxidation, is clearly reflected in the pharmacokinetics and the chemical fate of the fluorine label observed in mice: The odd-numbered compound, 17- 18 F- heptadecanoic acid, is catabolized to β- 18 F-propionic acid while the even-numbered 16- 18 F-hexadecanoic acid ends up with 18 F-fluoroacetic acid entering the citric cycle. Further degradation, i.e. dehalogenation, only occurs in the case of 17- 18 F-heptadecanoic acid yielding free 18 F- fluoride which can be detected in high yield among its metabolites [2]. With respect to diagnostic methods for the localisation of thrombi, the protein urokinase labelled with 18 F- fluoroacetic acid could be a useful compound, since it is expected that it will be concentrated in the thrombus thus giving the possibility of localisation by positron- emission tomography. 18 F-fluoroacetic acid has therefore been prepared carrier-free in order to prevent the occupation of active sites in urokinase. For the study of regional metabolism in brain, 2- 18 F- nicotinic acid diethylamide is potentially useful. The nonhalogenated compound is known to be a centrally acting pharmaceutical. Preparation of the 18 F-labelled compound was carried out by a similar procedure as in the case of the fatty acids starting from the corresponding chloro- compound. By this method optimum radiochemical yields up to 46% could be obtained. Preliminary results in experiments with mice show a fast accumulation of 18 F-activity in the brain within the first seconds after injection, followed by a slower decrease [3].
Read full abstract